SEC Tracker
Get the app

Supernus INDV

Supernus adjusts conversion rate for convertible notes

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Conversion rate increased to 30.9355 shares per $1,000 principal
  2. Conversion price set at $32.33 per share
  3. No bondholders converted bonds to common stock

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Supernus files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025
  2. Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
  3. Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
  4. Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
  5. Supernus Pharmaceuticals SUPN public float $1.7B, Jun 30, 2025